{"id":"alemtuzumab-plus-fludarabine","safety":{"commonSideEffects":[{"rate":"50%","effect":"Neutropenia"},{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alemtuzumab works by depleting lymphocytes, while fludarabine inhibits the proliferation of cancer cells.","oneSentence":"Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:58.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT01659606","phase":"PHASE2","title":"Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome","enrollment":40},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT04416984","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2020-05-21","conditions":"Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma","enrollment":160},{"nctId":"NCT03939026","phase":"PHASE1","title":"Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma","status":"COMPLETED","sponsor":"Allogene Therapeutics","startDate":"2019-05-01","conditions":"Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma","enrollment":50},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT04528355","phase":"","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2020-08-20","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":50},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT04232085","phase":"PHASE2","title":"Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-12","conditions":"Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure","enrollment":27},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT01966367","phase":"PHASE1, PHASE2","title":"CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-03","conditions":"Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia","enrollment":37},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT02179359","phase":"NA","title":"Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-09-02","conditions":"Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia","enrollment":38},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT04018937","phase":"PHASE2","title":"Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-03-22","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT01050855","phase":"PHASE2","title":"Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2008-01","conditions":"Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies","enrollment":75},{"nctId":"NCT02626715","phase":"PHASE2","title":"Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS","status":"COMPLETED","sponsor":"Randy Windreich","startDate":"2015-09-04","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":21},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT00408447","phase":"PHASE2","title":"Stem Cell Transplant in Sickle Cell Disease and Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2004-09","conditions":"Sickle Cell Disease, Beta Thalassemia","enrollment":53},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT03821610","phase":"PHASE2","title":"A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2018-11-22","conditions":"Acute Lymphoblastic Leukemia","enrollment":242},{"nctId":"NCT00047060","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2002-07-30","conditions":"Mycosis Fungoides, Sezary Syndrome","enrollment":5},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT00745420","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT01998633","phase":"PHASE2","title":"Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2013-12","conditions":"Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease","enrollment":47},{"nctId":"NCT01877837","phase":"PHASE3","title":"Stem Cell Transplantation for Sickle Cell Anemia","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2011-06","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT01186640","phase":"PHASE2","title":"Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2010-06","conditions":"T-cell-prolymphocytic Leukemia","enrollment":16},{"nctId":"NCT02497404","phase":"PHASE2","title":"Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-02-13","conditions":"Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes","enrollment":40},{"nctId":"NCT02435901","phase":"PHASE1, PHASE2","title":"HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2008-12","conditions":"Sickle Cell Disease, Beta Thalassemia-Major","enrollment":29},{"nctId":"NCT00881556","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-08-20","conditions":"Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT00536978","phase":"PHASE2","title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-09","conditions":"Lymphoma, Leukemia","enrollment":22},{"nctId":"NCT00578292","phase":"NA","title":"Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2004-02","conditions":"Thalassemia","enrollment":10},{"nctId":"NCT00566696","phase":"PHASE2","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-14","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML)","enrollment":73},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT01596699","phase":"PHASE2","title":"Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2012-05-24","conditions":"Myeloid Malignancy, Bone Marrow Failure Syndrome, Transfusion-dependent Red Blood Cell (RBC) Defect","enrollment":16},{"nctId":"NCT00553098","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-06","conditions":"Immunodeficiency Syndrome, Non-Cancer Diagnosis","enrollment":29},{"nctId":"NCT00040846","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2001-11","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":60},{"nctId":"NCT00040417","phase":"PHASE2","title":"Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2000-08","conditions":"Sickle Cell Anemia, Hemoglobinopathy, Thalassemia","enrollment":15},{"nctId":"NCT00048412","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2000-06","conditions":"Myelodysplastic Disorders, Leukemia, Multiple Myeloma","enrollment":40},{"nctId":"NCT00048399","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2000-12","conditions":"Graft Failure","enrollment":40},{"nctId":"NCT00085449","phase":"PHASE1, PHASE2","title":"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","status":"WITHDRAWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-05","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT04154735","phase":"PHASE2","title":"Autologous Transplant Targeted Against Crohn's","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT01392079","phase":"PHASE2","title":"Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2008-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT01013441","phase":"PHASE1","title":"CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT00775931","phase":"PHASE2, PHASE3","title":"Allogeneic Transplantation For Severe Osteopetrosis","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2008-08","conditions":"Severe Osteopetrosis","enrollment":7},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT00634881","phase":"PHASE1, PHASE2","title":"Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2003-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT00943319","phase":"PHASE1, PHASE2","title":"Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":50},{"nctId":"NCT01422603","phase":"PHASE1, PHASE2","title":"Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2011-02","conditions":"Acute Myeloid Leukaemia, Myelodysplasia","enrollment":9},{"nctId":"NCT01049854","phase":"PHASE2","title":"CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2011-09","conditions":"Leukemia, Lymphoma, Bone Marrow Failure","enrollment":20},{"nctId":"NCT00278512","phase":"PHASE1","title":"Hematopoietic Stem Cell Support in Vasculitis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-08","conditions":"Vasculitis","enrollment":7},{"nctId":"NCT00282412","phase":"PHASE1","title":"Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2002-09","conditions":"Rheumatoid Arthritis","enrollment":4},{"nctId":"NCT00590460","phase":"PHASE1, PHASE2","title":"Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2001-07","conditions":"Fanconi Anemia, Severe Aplastic Anemia","enrollment":5},{"nctId":"NCT00278213","phase":"PHASE2","title":"Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2002-09","conditions":"Prolymphocytic Leukemia","enrollment":17},{"nctId":"NCT00618540","phase":"PHASE2","title":"Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Histiocytosis, Langerhans-cell","enrollment":1},{"nctId":"NCT00176865","phase":"PHASE2","title":"Stem Cell Transplant for Immunologic or Histiocytic Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-08","conditions":"Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome","enrollment":19},{"nctId":"NCT01005576","phase":"PHASE2","title":"Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-01","conditions":"Severe Thalassemia","enrollment":21},{"nctId":"NCT00565981","phase":"PHASE2","title":"A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2004-03","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":10},{"nctId":"NCT00455312","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-08","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":36},{"nctId":"NCT00301834","phase":"PHASE2","title":"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-01","conditions":"Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia","enrollment":35},{"nctId":"NCT00416884","phase":"PHASE2","title":"Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-05","conditions":"Leukemia","enrollment":1},{"nctId":"NCT02653196","phase":"EARLY_PHASE1","title":"A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2015-09","conditions":"Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":1},{"nctId":"NCT00281983","phase":"PHASE1, PHASE2","title":"Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2000-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":100},{"nctId":"NCT00448357","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":54},{"nctId":"NCT00118352","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-03","conditions":"Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":12},{"nctId":"NCT02512679","phase":"PHASE2","title":"Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells","status":"TERMINATED","sponsor":"Children's Hospital Los Angeles","startDate":"2007-02","conditions":"Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation","enrollment":20},{"nctId":"NCT00104975","phase":"PHASE1","title":"Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT00683046","phase":"PHASE2","title":"T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-11","conditions":"Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia","enrollment":204},{"nctId":"NCT00058825","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant for Hematologic Diseases","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2000-08","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT00147901","phase":"PHASE2","title":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2005-01","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":61},{"nctId":"NCT00276809","phase":"PHASE2","title":"Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2001-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT00206726","phase":"PHASE2","title":"Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-05","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":60},{"nctId":"NCT00004857","phase":"PHASE2","title":"Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-01","conditions":"Leukemia","enrollment":86},{"nctId":"NCT00849745","phase":"PHASE1","title":"Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases","status":"TERMINATED","sponsor":"Duke University","startDate":"2003-01","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":4},{"nctId":"NCT00579111","phase":"PHASE1, PHASE2","title":"Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2007-06","conditions":"Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT01518153","phase":"PHASE2","title":"Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":16},{"nctId":"NCT00056979","phase":"PHASE1, PHASE2","title":"Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2002-06","conditions":"Inherited Metabolic Storage Diseases","enrollment":2},{"nctId":"NCT02529839","phase":"NA","title":"Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-10","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT02520895","phase":"","title":"Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2010-09","conditions":"LYMPHOMA","enrollment":98},{"nctId":"NCT00073879","phase":"NA","title":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2003-04","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT00744692","phase":"PHASE1","title":"Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-10","conditions":"Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures","enrollment":22},{"nctId":"NCT00349349","phase":"PHASE2","title":"HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Leukaemia, Lymphocytic, Chronic","enrollment":223},{"nctId":"NCT00597714","phase":"PHASE2","title":"Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant","status":"COMPLETED","sponsor":"David Rizzieri, MD","startDate":"2008-02","conditions":"Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma","enrollment":264},{"nctId":"NCT00098670","phase":"PHASE2","title":"Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10","conditions":"B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia","enrollment":102},{"nctId":"NCT00684255","phase":"PHASE1","title":"Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2007-08","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":1},{"nctId":"NCT00086580","phase":"PHASE3","title":"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-07","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":335},{"nctId":"NCT00586274","phase":"PHASE1","title":"Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2002-03","conditions":"FANCONI ANEMIA","enrollment":1},{"nctId":"NCT00021151","phase":"NA","title":"Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-01","conditions":"Leukemia","enrollment":2},{"nctId":"NCT00818961","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer","status":"TERMINATED","sponsor":"Northside Hospital, Inc.","startDate":"2005-05","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":36},{"nctId":"NCT01679041","phase":"PHASE2","title":"High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment","status":"TERMINATED","sponsor":"Seah Lim M.D.","startDate":"2012-11","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT00274976","phase":"PHASE2","title":"Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2002-09","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Alemtuzumab plus Fludarabine","genericName":"Alemtuzumab plus Fludarabine","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis. Used for Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}